Gilead bol­sters its case for block­buster hope­ful fil­go­tinib as FDA pon­ders its de­ci­sion

Be­fore remde­sivir soaked up the spot­light amid the coro­n­avirus cri­sis, Gilead’s fil­go­tinib was the star ex­per­i­men­tal drug tapped to rake in bil­lions com­pet­ing with oth­er JAK in­hibitors made by ri­vals in­clud­ing Ab­b­Vie and Eli Lil­ly.

Now, long term da­ta on the drug — dis­cov­ered by Gilead’s part­ners at Gala­pa­gos and post­ed as part of a vir­tu­al med­ical con­fer­ence — have so­lid­i­fied the dura­bil­i­ty and safe­ty of fil­go­tinib in pa­tients with rheuma­toid arthri­tis, span­ning da­ta from three late-stage tri­als. An FDA de­ci­sion on the drug is ex­pect­ed this year.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.